CysLT1 Antagonist Q8

• CAT Number: I035297
• CAS Number: 1541762-55-3
• Molecular Formula: C17H14ClNO2
• Molecular Weight: 299.75
• Purity: ≥95%
• IUPAC Name: 2-[(E)-2-quinolin-2-ylethenyl]benzene-1,4-diol;hydrochloride
• InChI: InChI=1S/C17H13NO2.ClH/c19-15-9-10-17(20)13(11-15)6-8-14-7-5-12-3-1-2-4-16(12)18-14;/h1-11,19-20H;1H/b8-6+
• SMILES: C1=CC=C2C(=C1)C=CC(=N2)/C=C/C3=C(C=CC(=C3)O)O.Cl

CysLT1 antagonist Q8 inhibits developmental angiogenesis in transgenic fluorescent zebrafish, and inhibits human microvascular endothelial cell (HMEC-1) proliferation, tubule formation, and migration. CysLT1 antagonist Q8 elicits antiangiogenic effects in a VEGF-independent in vitro model of angiogenesis and exerts an additive antiangiogenic response with the anti-VEGF biologic bevacizumab.
KEYWORDS: CysLT1 Antagonist Q8 | supplier | CysLT1 antagonist | CAS [1541762-55-3] | [1541762-52-0] | Cysteinyl leukotrienes | CysLT | Antagonist | Receptors | Angiogenesis | Antiangiogenic

Reference

CT Butler et al. A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab. J Biol Chem. 2017 Mar 3;292(9):3552-3567.